ARS PHARMACEUTICALS INC. - COMMON STOCK

ARS Pharma Announces Favorable Topline Results from Repeat Dosing Study of neffy® (Epinephrine Nasal Spray) Under Nasal Allergen Challenge Conditions, Readies Data for Response to FDA’s Complete Response Letter

20 фев 2024 08:01:00 Источник Nasdaq GlobeNewswire

ARS Pharmaceuticals to Present Positive Clinical Efficacy Data for neffy® (epinephrine nasal spray) at 2024 AAAAI Annual Meeting

05 фев 2024 08:01:00 Источник Nasdaq GlobeNewswire

ARS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Updates

09 ноя 2023 15:00:00 Источник Nasdaq GlobeNewswire

ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis

09 ноя 2023 10:02:36 Источник Nasdaq GlobeNewswire

ARS Pharmaceuticals Announces Scheduling of a Type A Meeting with the U.S. FDA for neffy® (epinephrine nasal spray)

06 окт 2023 08:03:00 Источник Nasdaq GlobeNewswire

Single and Repeat Dose Clinical Study of neffy (epinephrine nasal spray) Published in the Journal of Allergy and Clinical Immunology

03 окт 2023 08:03:40 Источник Nasdaq GlobeNewswire

FDA Issues Complete Response Letter for neffy® (epinephrine nasal spray) New Drug Application with Request for Additional Study

19 сен 2023 21:49:48 Источник Nasdaq GlobeNewswire

ARS Reports Second Quarter 2023 Financial Results and Provides Business Updates

10 авг 2023 15:00:00 Источник Nasdaq GlobeNewswire

ARS Pharmaceuticals Announces PDUFA Date Extension for neffy® (Intranasal (IN) Epinephrine) for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis

20 июн 2023 07:00:01 Источник Nasdaq GlobeNewswire

ARS Pharmaceuticals Highlights Progress and Reports First Quarter 2023 Financial Results

15 май 2023 08:00:00 Источник Nasdaq GlobeNewswire

FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for neffy® (Intranasal (IN) Epinephrine) for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis

11 май 2023 18:01:24 Источник Nasdaq GlobeNewswire

ARS Pharmaceuticals Announces Availability of Briefing Documents for FDA Advisory Committee Meeting on neffy® for the Treatment of Type I Allergic Reactions Including Anaphylaxis

09 май 2023 08:10:46 Источник Nasdaq GlobeNewswire

ARS Pharmaceuticals Announces FDA Advisory Committee for neffy® for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis

28 мар 2023 08:39:51 Источник Nasdaq GlobeNewswire

ARS Pharmaceuticals Highlights Progress and Reports Fourth Quarter and Full Year 2022 Financial Results

23 мар 2023 15:01:00 Источник Nasdaq GlobeNewswire

ARS Pharmaceuticals Announces Presentation of Data Supporting neffy (epinephrine nasal spray) and Real-World Burden of Needle Injectors

23 фев 2023 15:01:00 Источник Nasdaq GlobeNewswire

ARS Pharmaceuticals Reacquires European Marketing Rights to neffy® (ARS-1) for the Treatment of Type I Allergic Reactions Including Anaphylaxis

22 фев 2023 15:05:01 Источник Nasdaq GlobeNewswire

ARS Pharmaceuticals to Participate in the SVB Securities Virtual Global Biopharma Conference 2023

09 фев 2023 05:30:00 Источник Nasdaq GlobeNewswire

ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis

10 ноя 2022 07:00:03 Источник Nasdaq GlobeNewswire

ARS Pharmaceuticals Closes Merger with Silverback Therapeutics

08 ноя 2022 15:02:00 Источник Nasdaq GlobeNewswire